Big Pharma stocks don't usually drop by double-digits over the course of a month, but that's exactly what happened to British pharma giant AstraZeneca plc (NYSE:AZN) in July. Due to the late-stage failure of its lung cancer combination therapy ...
But making AstraZeneca plc an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of AZN entered into oversold territory, changing hands as low as $29.06 per share.
U.K. stocks slipped Thursday, marking their first loss in three sessions as drug heavyweight AstraZeneca PLC tumbled following a disappointing cancer-drug trial, while the pound pushed another leg higher against the dollar.
AstraZeneca PLC (AZN) delivered a increase of 0.17% return in recent trading session. LVM Capital Management Ltd. MI now owns 9,800 shares of the company's stock worth $305,000 after buying an additional 1,000 shares during the period.